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Synthesized Tripodal Amine as Potential Anti-Cancer Therapeutic
An Honors Thesis submitted in partial fulfillment of the requirements for Honors in Chemistry and
Biochemistry.
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Abigail Grace McNamee
Under the mentorship of Dr. Christine Whitlock
With additional mentorship of Dr. Timothy Tolentino
ABSTRACT
Cancer remains a prevalent disease today. This disease may manifest itself in many different ways
and affect a variety of tissues with everything from the brain to the blood. With this wide diversity
of cancer types, treatment can be complicated since there is not a “one size fits all” treatment for
the disease. Surgery, radiation, and chemotherapy are all options that must be weighed with their
benefits and side effects. Ultimately though, there are not enough effective treatment options
available for every type of cancer. This leaves many with the grim prognosis of never being cured.
With this clear need for more anti-cancer medicine, research is warranted into novel treatments and
drugs. A novel tris-indolyl iron-chelating drug GS02 was synthesized and tested for its potential
anti-cancer properties. The LD50 was determined using MTS assays against human cancer cell
lines and apoptosis assays were carried out with the PC3 cell line. Images of the cells were
collected using confocal imaging microscopy. Current results show a decrease in cell viability and
suggest that GS02 is inducing apoptosis in the PC3 cell line. Furthermore, the compound was
shown to be toxic within a specific concentration range which may be of interest for the potential of
a new chemotherapy agent. Given these results, GS02 warrants continued investigations into its
potential to trigger apoptosis in more human cancer cell lines.

Thesis Mentor:________________________
Dr. Christine Whitlock
Honors Director:_______________________
Dr. Steven Engel
April 2020
Chemistry and Biochemistry
University Honors Program
Georgia Southern University

2
Acknowledgments:
Cell culture labs were provided by the Chemistry and Biochemistry Department at Georgia
Southern University. Confocal microscope and flow cytometer access were provided by the Biology
Department at Georgia Southern University.
I would like to express my deep gratitude to Dr. Christine Whitlock for taking a chance on me and
allowing me to join her lab. She has been much more than a mentor to me and I appreciate the
excitement and enthusiasm for research which she has cultivated in me.
Many thanks also go to Dr. Timothy Tolentino for his patience in teaching me cell culture lab
techniques and having more confidence in my abilities than I did. His advice on all things ranging
from science to graduate schools to life are invaluable to me.
Finally, I would like to thank Amanda Wallace for welcoming me so excitedly into the Whitlock
Lab. Thanks also go to Noah Sherridan and Maegen Morrow for their patience as I tried to explain
things I had learned from research. The friendship I have received from Amanda, Noah, and
Maegen is truly a treasure and I am honored to have had them in my life as my “lab family.”

3
Introduction:
Cancer still remains as a prevalent disease today. This disease may manifest itself
in many different ways and affect a variety of tissues. Overall, cancer is a genetic disease
and arises with mutations in a cell’s DNA.1 These mutations can occur through genetic
inheritance, error in the DNA replication process, or through internal/external mutagens.
Oftentimes, these mutations result in uncontrolled cell growth and enable the cancerous
cell to bypass typical regulatory checkpoints in the cell cycle.1 The combination of
increased growth with fewer regulatory mechanisms to check for error in DNA
synthesis/repair makes it easy for cancer to grow and spread. Treatment can be
complicated since there is not a “one size fits all” treatment course and further
complications arise once the cancer becomes chemo-resistant. With this need for
improved medicine, research is warranted into potential cancer treatments and drugs.
With this clear need for a wider variety of treatment options, research has
continued in this field with focuses on different approaches. One area of interest in our
lab is using iron chelators as potential anti-cancer therapeutics. Iron chelators already
have therapeutic use in treating iron overload disease. These molecules function in
“grabbing” iron in the body and the result makes the iron easier for the body to excrete.
However, some researchers have turned their attention to exploiting this characteristic for
cancer treatment. Iron itself has many important biological functions and is critical to
maintaining homeostasis for an organism. Iron may be found in two different oxidation
states, Fe2+ and Fe3+, and is a vital micronutrient for many organisms.2 Iron is used in
biological functions such as DNA synthesis, oxygen transport through hemoglobin,
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production of energy, and macromolecule synthesis.2 Through the role iron has in these
vital processes, it is clear to see that iron is essential to any growing organism. The
rationale to using iron chelators as an anti-cancer therapeutic thus lies within limiting the
cancer cells accessibility to this important micronutrient, thus slowing and ideally
preventing cancer cell growth.3 Various studies have been performed which demonstrate
the promising results of
using iron chelators as a
cancer treatment. One
study investigated the
effects of deferoxamine
and deferasirox, two known iron chelators (Figure 1), on the proliferation and stemness
of cancer stem cells.6 The results gleaned first showed that having an ample supply of
iron enhances the proliferation of the cells then, when treated with iron chelators,
antiproliferative effects were observed along with a reduction in stemness markers.6
Another experimental
investigation into iron
chelators found that a
novel chelator,
super-polyphenol (SP),
in two forms (Figure 2)
was effective at
inducing apoptosis in various cancer cell lines.7 Furthermore, their findings suggested
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that the novel SP compound was safer for use than clinically available deferoxamine, thus
providing a potentially less toxic option for therapeutic use.7
Other researchers have discovered the antiproliferative effects
of an iron chelator VLX600 (Figure 3) on cancer cell lines and
the compound even proceeded to a phase-1 clinical trial.8
With designing testing for the anti-cancer properties of
GS02, apoptosis was the desired method of inducing cell death.
Apoptosis is pre-programmed cell death and can occur due to
some external signal or caused by the cell itself.9 Hallmarks of
this type of death include the expenditure of energy, thus it is an active form of dying,
and the breakdown of all membranes, including the nuclear membrane.9 Apoptosis is an
important part of homeostasis for an organism and disturbances in its regulation can lead
to serious diseases such as cancer.10,11 Often as seen in cancer, there is some sort of
inhibition of apoptosis which leads to the rapid, uncontrolled growth of cancerous cells.
The importance of apoptosis in cancer leads to a potential target, especially since
targeting apoptosis does not lead to inflammation like necrosis does (passive cell
death).9,12
The aims of this project are to test the potential anti-cancer properties of a novelly
synthesizied tris-indolyl amine, GS02. This compound’s structure is based on iron
chelators and is a TRENSOX derivative with indoles in place of quinolines.13
Cytotoxicity of GS02 will be tested against the PC3 cell line which is human prostate
cancer. Apoptosis is the targeted method of cell death and will be tested for using a
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cytotoxicity assay which may be used for measuring cell death.14 Further analysis will be
done using spectrophotometry and imaging techniques.

Methods and Materials:
Synthesis of GS02:
GS02 (tris(2-[indole-3-glyoxylamido]ethyl)amine), was synthesized using a
previously established procedure.13 Ether (200 mL) was added to indole (10.10 g) at 0 ℃,
then over a period of 15 minutes, oxalyl chloride (14.6 g) was added dropwise. The
reaction mixture stirred for 30 minutes, then was filtered and a yellow solid was
collected. THF (50 mL) was used to dissolve the yellow solid and once dissolved, the
mixture was placed in an ice bath. TREN (6.12 g, 42.0 mmol), TEA (4.27 g, 42.3 mmol),
and THF (10 mL) were combined and added to the 0 ℃ solution of dissolved solid. The
solution was allowed to stir for 1 hour at 0 ℃ . Afterward, it was filtered and the filtrate
allowed to evaporate (Figure 1). A beige solid was collected (0.52 g, 0.79 mmol, 2.7%)
after recrystallization from MeOH.

Figure 4. A colorful synthesis of GS02. From left to right: stirring the reaction for 30
min, filtering the solid, stirring for 1 hour, and filtering out the desired filtrate.
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Apoptosis Assay:
Cells were plated into a 96 well plate at a concentration of 7,500 cells per well
and incubated for 24 hours at 37°C. Mitochondrial membrane was labeled via incubation
with Mito-tracker red for 30 minutes at 37°C. The cells were then washed and
resuspended in cell culture media. Control cells were incubated in the normal cell culture
media. Other cells were treated with either 1% DMSO, 2 mM staurosporine, or 74.8 µM
GS02 with the DMSO and staurosporine treatments serving as negative and positive
controls respectively. Three samples were taken from each experimental condition at 2, 4,
8, and 24 hour time points. Acridine Orange was used to fluorescently label cells
previously stained with Mito-tracker red. Cells were also fluorescently labeled with either
Caspase 3, 7 green detection reagent and Sytox Aadvanced. A BD Accuri C6 flow
cytometer was used for cytometric analysis.

Capturing Images of Cells:
PC3 cells were plated onto microscope slide cell culture disks and treated with
74.8 µM GS02 and labeled with MitoTracker Red and Hoechst 422. Cells were fixed at
the 12 hour time point and images collected using a Zeiss confocal imaging microscope.
Images were collected showing only the fluorescence of one dye at a time, then images
were collected simultaneously showing both dyes.
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Data and Results:

Figure 5. Synthesis of GS02. Pictorial representation of the synthesis of potential cancer
therapeutic GS02 showing structures of materials and end product.

Figure 6. Cells were incubated with CellEvent Caspase 3, 7 green detection reagent, a
four-amino acid peptide (DEVD) conjugated to a nucleic acid-binding dye which is
non-fluorescent until cleaved from the peptide and bound to DNA. Fluorescent intensity
was measured at 2, 4, 8, and 24 hours. Control, DMSO, Staurosporine (Staur), and GS02
were the various treatments.
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Figure 7. Relative fluorescent intensity of Sytox across varying time points.
Cells were incubated with Sytox Aadvanced, a DNA binding dye which becomes
fluorescent upon binding to DNA. As such fluorescence indicates cell death. Treatments
were Control, DMSO, Staur, and GS02 with data gathered at 2, 4, 8, and 24 hours.

Figure 8. Relative fluorescent intensity of Mito-Tracker Red across varying time
points. Cells were fluorescently labeled with Mito-tracker red which fluoresces red when
bound to intact mitochondrial membranes. Samples of Control, DMSO, Staur, and GS02
were read at time points of 2, 4, 8, and 24 hours.
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Figure 9. MitoTracker Red stained PC3 cells at 12 hour time point. PC3 cells were
treated with GS02 and labeled with the fluorescent indicator MitoTracker Red. This
stains intact mitochondrial membrane. At the 12 hour time point, the PC3 cells were
fixed. Z-stacked images were collected using a Zeiss confocal microscope.

Figure 10. Hoechst 422 stained PC3 cells at 12 hour timepoint. PC3 cells were treated
with GS02 and labeled with the fluorescent indicator Hoechst 422. Hoechst 422 is a DNA
intercalator that fluoresces when bound to DNA. At the 12 hour time point, the PC3 cells
were fixed. Z-stacked images were collected using a Zeiss confocal microscope.
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Figure 11. PC3 cell treated with GS02 at 12 hour time point. PC3 cells were treated
with GS02 and fluorescently labeled with Hoechst 422 stain and MitoTracker Red. At the
12 hour time point, the PC3 cells were fixed. Z-stacked images were collected using a
Zeiss confocal microscope. The figure shows fluorescent activity from both fluorescent
indicators of the Hoechst 422 (green) and MitoTracker Red (red) stains.

Figure 12. GS02 treated PC3 cells with overlapping of fluorescent indicators at 12
hours. Multiple PC3 cells shown with both indicators of Hoechst 422 and MitoTracker
Red indicators present. Overlapping of the red MitoTracker Red indicator and the green
Hoechst 422 stain show where both are present with an orange/yellow color.
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Discussion:
Synthesis of GS02 was carried out and previous analysis with NMR and IR
spectroscopy was executed to confirm the structure (Figure 4,5).13 Various assays were
performed to determine the potential anti-cancer properties of GS02. The flow cytometry
data yielded interesting results. The first fluorescent dye used was Caspase 3,7 detection
reagent which is activated in the presence of caspases 3 and 7. Once activated, the dye
will fluoresce once bound to DNA.The presence of fluorescence indicates that cells are
dying and potentially dying from apoptosis since the dye is able to reach DNA through
the nuclear membrane and there are caspase enzymes present in a high enough
concentration to activate the detection reagent. Apoptosis is characterized by a presence
of the caspase enzymes 3 and 7 and the nuclear membrane does breakdown which is in
contrast with other methods of cell death. GS02 had a spike in fluorescence at 2 hours
lowered by the 4 hour time point and remained near constant afterwards. Similarly, the
positive control staurosporine shows a spike, much higher than GS02, at the 2 hour time
point which diminishes as time continues. These spikes for both staurosporine and GS02
are higher than the levels of control and it is inferred that cells are dying and potentially
through apoptosis (Figure 6).
Confirmation of cell death was determined using another fluorescent dye, Sytox
Aadvanced. The presence of Sytox fluorescence indicates cell death, but does not indicate
which method of cell death is occuring. The control level of relative fluorescent intensity
remained near constant across time points. Both the staurosporine and GS02 treatments
had similar trends in observing a decrease in fluorescent intensity at 2 hours followed by
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an increase later on. Staurosporin did have higher levels of relative fluorescent intensity
and thus is potentially more cytotoxic than GS02, but both treatments were shown to
increase cell death. Overall, the decrease in relative fluorescence intensity seen in the
treatment with GS02 provides support that apoptosis is the cause of cell death (Figure 7).
To further gain insight into the type of cell death, the Mito-Tracker Red dye was
used. This is useful in that it fluoresces red when bound to intact mitochondrial
membrane. At the 2 hour time point, all treatments remain at similar levels of relative
fluorescence intensity. As time proceeds, the control treatment remains at steady levels
which would be expected. Once the 8 hour time point is reached, a decrease in
fluorescent intensity is observed in the other three treatments. Interestingly, GS02 shows
a swifter decrease in fluorescence than does staurosporine, potentially indicating a swifter
breakdown of mitochondrial membranes. The overall decrease in relative fluorescent
intensity of GS02 suggests that the mitochondrial membrane is breaking down, a
hallmark present in apoptosis which is characterized by the breakdown of various
membranes in the cell (Figure 8).
Further insights into the effects of GS02 were gained through confocal imaging of
the cells. As previously done, Mito-Tracker Red was used to stain for intact
mitochondrial membrane. Once the cell was fixed, the z-stacked image obtained showed
fluorescent activity through varying levels of the cell. This showed that there was intact
mitochondrial membrane at the 12 hour time point (Figure 9). Another dye, Hoechst 422,
was used as well. This dye was chosen since it fluoresces green once bound to DNA.
Imaging of the fixed cell at the 12 hour time point showed clear fluorescent activity
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across the z-stacked images. The incidence of green fluorescence indicates that the
nuclear membrane is breaking down and apoptosis is likely occurring (Figure 10). Taken
together, both sets of imaging data provide insight that at the 12 hour time point, the cell
is still undergoing apoptosis and has not been completely destroyed. The simultaneous
presence of both intact mitochondrial membrane and the ability for the Hoechst 422 dye
to travel through the nucleus and bind to DNA help provide a reference point as to when
the activity of GS02 begins.
An overlay of the previous two images was done to investigate any other insights
that the date might provide. Interestingly, once the z-stacked images were overlaid of the
same cell, green and red fluorescence was seen, but also an orange color was suddenly
present. This indicated a colocalization occuring in the cell. The presence of both intact
mitochondrial membrane and Hoechst 422 dye bound to DNA showed that the
mitochondria of the cell was slowly having holes poked through it, likely due to the
caspase enzyme cascade in apoptosis (Figure 11). A broader image was gathered to
analyze whether this was local phenomena to the individual cell and found that at the 12
hour time point, many other PC3 cells also had colocalization of the dyes and as such,
indicated the presence of intact mitochondrial membrane along with holes being present
in the membrane (Figure 12). This further indicated that apoptosis was occurring and also
showed that the Hoechst 422 would bind not just to nuclear DNA, but also to
mitochondrial DNA. Taken together, the data supports the claim that GS02 does possess
anti-cancer properties and is at least cytotoxic to human prostate cancer. Along with
being toxic to cancer cells, it also is highly likely that the mode of cell death induced is
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apoptosis as seen from the breakdown of mitochondrial membrane and increase in the
presence of caspase enzymes 3 and 7.

Conclusion and Future Work:
A novel, tripodal amine GS02 was synthesized and used in testing against the PC3
cell line as a potential anti-cancer therapeutic. Combining the data from various
fluorescent dyes and confocal imaging of cells supports the claim that GS02 is cytotoxic
to PC3 cells and is inducing apoptosis. This set of data offers a promising foundation for
further research with GS02 and other iron chelators of similar structure. Other derivatives
of GS02 may have similar or even more potent effects against cancer cell lines and it
would be of great interest to synthesize a variety of related compounds for testing. The
experiments done above could be repeated except with more time points to analyze
exactly when GS02 induces apoptosis and the time it takes for it to completely kill the
population. This will likely be before the 12 hour time point since the confocal images
show progression of apoptosis, but not the completion. To continue developing GS02,
more testing against other cancerous cell lines needs to be completed to identify whether
the cytotoxic effects of GS02 are unique to the PC3 or if there is another cancer against
which it might be a more effective treatment option. In particular, it would be noteworthy
to see the effect against a lung cancer cell line since the lungs would be a location of
much iron due to the gas exchange that occurs with the transportation of oxygen in
hemoglobin, a iron-containing protein. Also, there is currently no data for GS02’s effect
on healthy cells. A study done on various primary cells should be completed to determine
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whether GS02 is more or less toxic to healthy cells than cancerous cells. Still another
avenue for investigation is the mechanism by which GS02 induces apoptosis. Western
Blots and immunoblots would be of interest as to identify which proteins might be getting
interrupted and which pathway in the cell is triggering the signal for apoptosis. Overall,
the results of this experiment will help provide the foundation for further analysis and
development of potential anti-cancer agents. This is a necessary step as other researchers
continue to investigate potential treatments for those afflicted with cancer.
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